
    
      The study will comprise:

        -  A screening period of maximum 28 days;

        -  Two treatment periods:

             -  Treatment Period 1 starts with admission to the Clinical Unit on Day -1, followed
                by dosing on Day 1 with the assigned treatment (A, B, C, or D) as per assigned
                cohort and treatment sequence, followed by a washout period of at least 14 days.

             -  Treatment Period 2 starts with admission to Clinical Unit on Day -1, followed by
                dosing on Day 1 with cross-over treatment as per assigned cohort, followed by a
                follow-up period of 7 to 10 days.

        -  A follow-up visit/early termination visit at 7 to 10 days after the last investigation
           medicinal product (IMP) administration.

      Subjects will be assigned to either Cohort 1 (tacrolimus) or to Cohort 2 (cyclosporin). Each
      cohort will have 2 treatment periods. Subjects in each cohort will be randomly assigned to
      one of 2 treatment sequences (AB|BA or CD|DC) where,

        -  Treatment A: Tacrolimus

        -  Treatment B: Tacrolimus + SZC

        -  Treatment C: Cyclosporin

        -  Treatment D: Cyclosporin + SZC
    
  